GlobeNewswire by notified

Clean Motion delivers tailored EVIG to the NEOM Island Sindalah

Share

The electric vehicle manufacturer Clean Motion announces that the delivery of vehicles to NEOM is in full swing.

In May, Clean Motion was awarded a framework agreement with NEOM. The scope was to develop and deliver an integrated solution for last-mile deliveries tailored specifically for NEOM.

NEOM, located in northwest Saudi Arabia, is an innovative and visionary infrastructure project built from scratch. The island of Sindalah, in the Red Sea, is set to be the first destination to welcome visitors in the beginning of 2024. Clean Motion's comprehensive last-mile delivery system, which includes vehicles, trailers, and roll cages, will be responsible for streamlining logistics on the island.

The vehicles being dispatched have been specially tailored to meet NEOM's distinct needs, now also incorporating waste management capabilities.

"Our ability to innovate and deliver in a dynamic environment like NEOM showcases our company's strengths," says Christoffer Sveder, Commercial Director at Clean Motion. "It affirms we're on the right trajectory with our new solar-powered platform and vehicle EVIG."

For further information, please contact:
Christoffer Sveder, Commercial Director                
Clean Motion AB                        
Phone: +4670 611 26 98                        
Email: christoffer.sveder@cleanmotion.se

About Clean Motion AB
Clean Motion AB is a Swedish company that manufactures and sells truly sustainable vehicles for cities. The vehicles are locally produced and based on energy and resource efficiency, to maximize the adoption of electric vehicles globally. The company vision is to offer urban mobility-charged with solar energy and therefore offers light electric vehicles with low energy consumption to meet the urban transport challenges of the 2000s.

Clean Motion AB is listed on First North Growth Market on Nasdaq Stockholm. Certified Adviser is G&W Fondkommission. For further information, please visit: https://www.cleanmotion.se

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Dassault Aviation Wins Choiseul “Strategic Company” Award29.11.2023 10:21:57 CET | Press release

Dassault Aviation Wins Choiseul “Strategic Company” Award (Saint-Cloud, November 29, 2023) – Dassault Aviation is particularly proud to have received the 2023 Strategic Company Award as part of the Institut Choiseul’s Sovereignty Initiative. The institute believes that strategic companies represent one of the many facets of national strength. Award recipients are known for their capacity to effectively mobilize resources and know-how, and to provide solutions that meet national priorities. They are a cornerstone of French strategic heritage. Dassault Aviation is an industrial architect and complex systems integrator, a developer of strategic technologies, a major national exporter, a core shareholder of the Thales Group and a vital player in an industrial landscape that includes hundreds of business and service partners. The company is at the core of the French sovereign defense ecosystem. Dassault Aviation is also the only non-American company that manufactures high-end business jets.

Company announcement no 17/2023 Interim Report Q3 202329.11.2023 10:20:00 CET | Press release

Interim Report Q3 2023 EBITDA fixed herd prices (FHP) for Q3 2023 increased to 13.663 mEUR (Q3 2022: 10.463 kEUR), corresponding to an EBITDA margin FHP of 36.3% (Q3 2022: 32.5%). The quarterly EBITDA in Q3 2023 increased by 3.201 kEUR (compared to Q3 2022). Nevertheless, this consist of many parts this quarter: Russia harvest negative with 2,7 mEUR (from 4,1 to 1,5 mEUR) whereas remaining Russian business compensate positive with 3,0 mEUR partly due to FX (cost in EUR lower), Lithuania negative effects from one-off subsidy in Q3 2022 (2,5 mEUR), but combined sales/feed with positive effect of 4.9 mEUR and lower cost levels with 0.5 mEUR driven by utilities. Sales prices combined down, as they in Q3 2023 were 1.59 EUR/kg live weight, down from 1.62 EUR/kg Q2 2022 equal to EUR 0,8m, but EURRUB effects this picture highly as Lithuanian sales prices in EUR is up 23% and Russian in RUB is up 13%. Feed prices in Q3 2023 were 261 EUR/T (compared to 332 EUR/T Q3 2022). End September 2023 on h

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®29.11.2023 10:00:00 CET | Press release

The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects, met its primary endpoints. “These results demonstrate the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities,” said Joseph McClellan, Chief Scientific Officer. “As we progress more biosimilar candidates through clinical development and approval, w